Breast Cancer Symposium - Enhancing Clinical Care Through Collaboration

Comparative Effectiveness Remains a Valuable Tool for Assessing Cancer Therapies in Real-World Setting

Gary H. Lyman, MD, MPH, FASCO, FRCP (Edin), reviews the benefits and challenges of comparative effectiveness for breast cancer treatment, concluding that although randomized control trials remain the gold standard for assessing efficacy, additional methodological tools are available that may help identify the most effective cancer therapy.